<DOC>
	<DOCNO>NCT01159600</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability two dos BI 10773 compare placebo give 24 week add-on therapy metformin metformin plus sulfonylurea patient Typ 2 Diabetes Mellitus insufficient glycaemic control .</brief_summary>
	<brief_title>Efficacy Safety Study With Empagliflozin ( BI 10773 ) v . Placebo add-on Metformin Metformin Plus Sulfonylurea Over 24 Weeks Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis type 2 diabetes mellitus prior inform consent 2 . Male female patient diet exercise regimen pretreated immediate release metformin immediate release metformin plus sulfonylurea ( see minimum dos ) . The treatment regimen unchanged 12 week prior randomisation . Minimum dose metformin : &gt; = 1500 mg/day maximum tolerate dose maximum dose accord local label Minimum dose sulfonylurea : &gt; = half maximal recommend dose maximum tolerate dose maximum dose accord local label 3 . HbA1c &gt; = 7.0 % &lt; = 11 % Visit 1 ( screen ) order eligible randomise treatment HbA1c &gt; 11 % Visit 1 ( screen ) order eligible openlabel treatment arm ( 25 mg BI 10773 ) 4 . Age &gt; = 18 5 . Body Mass Index ( BM ) I &lt; = 45 kg/m2 ( Body Mass Index ) Visit 1 ( Screening ) 6 . Signed date write informed consent date Visit 1 accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : 1 . Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast placebo runin confirm second measurement ( day ) 2 . Any antidiabetic drug within 12 week prior randomisation except mention inclusion criterion 2 3 . Myocardial infarction , stroke transient ischemic attack ( TIA ) within 3 month prior inform consent 4 . Indication liver disease , define serum level either ALT ( SGPT ) , AST ( SGOT ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine screen and/or runin phase 5 . Impaired renal function , define eGFR &lt; 30 ml/min ( severe renal impairment ) determine screen and/or runin phase 6 . Bariatric surgery within past two year gastrointestinal surgery induce chronic malabsorption 7 . Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year 8 . Contraindications metformin and/or sulfonylurea accord local label patient enter study respective background therapy 9 . Blood dyscrasia disorder cause haemolysis unstable Red Blood Cell ( e.g . malaria , babesiosis , haemolytic anaemia ) 10 . Treatment antiobesity drug ( e.g . sibutramine , orlistat ) 3 month prior inform consent treatment time screen ( i.e . surgery , aggressive diet regimen , etc . ) lead unstable body weight 11 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except Typ 2 Diabetes 12 . Premenopausal woman ( last menstruation Â¿ 1 year prior informed consent ) : nursing pregnant childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include tubal ligation , transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , sexual abstinence ( acceptable local authority ) , double barrier method vasectomise partner 13 . Alcohol drug abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake 14 . Participation another trial investigational drug within 30 day prior inform consent 15 . Any clinical condition would jeopardize patient safety participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>